F1ash posted a great response to some of the bashing elsewhere. As he is on mobile and can't re-post here, here it is (I can't transfer the charts and other illustrations here):
F1ash Thursday, 10/01/15 10:03:23 AM
Re: Chemdeps post# 123915
Post #123949 of 123961
In fairness, it looks like your friend spends alot of time on the AVXL board, so I am not surprised that he is inadequately informed about Cellceutix"s drug candidates. Here are a few notes to help explain where I believe he is making less than accurate assertions!
"The current investor base is there almost exclusively for K"
Not why I invested here, and not where most of the legitimate commentary here is focused the majority of the time. Kevetrin is discussed when the news warrants. "Disappearing spleen lesion etc."
"The original claims made for Kevetrin for ALL solid tumors have evaporated. Will it be strong enough for even an orphan indication, and remember, it is still in PH1."
Phase 1 is recruiting the final two patients and I have to seriously question the DD that "Mr Jones" did when he invested here years ago. A quick peek at the Preclinical graphs indicate that Kevetrin alone had a variable response to different tumor types and is not likely a one drug cure for all cancers. Talk about setting the bar too high. What he missed and what many BP's may be excited about is the ability of Kevetrin to increase the effectiveness of current chemotherapy drugs. I imagine that a lot of companies would be interested in something which can extend the income generated by their current drugs by extending the time to resistance.
" Big Pharma had plenty of time to check out the technology as Poly was dying. No interest. My concern now is the competition. In BOM, there is a Big Phama standard of care, and since the purchase, my count was at least 2 more well funded drugs have been approved, with another at the same stage as B."
Not sure how many times this needs to be stated, but I guess at least once more. At the time of the Polymedix asset purchase Antibiotics were not in vogue! Big Pharma was not interested because typical antibiotics are not a huge revenue generator and if a company has to spend the same amount of money developing a drug it would be better to develop a cancer drug with huge margins than spend the same amount to develop an antibiotic. The government has changed that environment by targeting Antibiotic development. (GAIN Act)
Not sure if he is referring to (Magic Mouthwashs) as (Big Pharma's) Standard of Care. I wasn't even aware that Big Pharma got to set the Standard of Care thought that was determined by the health care facilities. I believe Brilacidin is being compared to the current SOC which is Ice chips. Brilacidin showed a 90% reduction in the days with OM, what was the effectiveness of the drugs he referenced. How are those other drugs for medical device coating?
" I remember when I was doing my research about psoriasis 3 years ago, through as I recall some adjunct of the national P foundation, and I was stunned to see about 25 drugs in active development for the various kinds of psoriasis. It seemed like every billion dollar big pharma had a candidate, not wanting to miss out on that lucrative market. I am sure several have now been approved, and P still is sitting there. Bottom line for me is the competition is fearsome and well funded. "
Notice the word "CURED"
"By SAR, the lead candidate Prurisol is selected. Prurisol in human xenograft model. The top row animals show a clean coat with no evidence of psoriasis, essentially showing that Prurisol cured the psoriasis in the mice. The bottom row shows the untreated control animals. - See more at: http://cellceutix.com/prurisol/#sthash.ybeXKLlr.dpuf
"In laboratory studies, Prurisol was found to be effective against psoriasis in animal models, both in induced psoriasis as well as a xenograft model with human psoriatic tissue. As shown in the image, Prurisol removed virtually all signs of psoriasis with no reoccurrence of the lesions.
The trial is another milestone for Cellceutix and the culmination of years of work in its efforts to develop this drug for the chronic and often painful condition of plaque psoriasis. Despite advancements in therapeutics for treating this condition, there remains an area of great unmet medical need for an option to often-used biologics, which are known to have side effects and contraindications and eventually lose effectiveness to many patients. Prurisol is Cellceutix's efforts to provide a solution to this substantial market.
Read more: http://www.nasdaq.com/press-release/cellceuti...z3nHDZtQSD
F1ash Thursday, 10/01/15 10:03:23 AM
Re: Chemdeps post# 123915
Post #123949 of 123961
In fairness, it looks like your friend spends alot of time on the AVXL board, so I am not surprised that he is inadequately informed about Cellceutix"s drug candidates. Here are a few notes to help explain where I believe he is making less than accurate assertions!
"The current investor base is there almost exclusively for K"
Not why I invested here, and not where most of the legitimate commentary here is focused the majority of the time. Kevetrin is discussed when the news warrants. "Disappearing spleen lesion etc."
"The original claims made for Kevetrin for ALL solid tumors have evaporated. Will it be strong enough for even an orphan indication, and remember, it is still in PH1."
Phase 1 is recruiting the final two patients and I have to seriously question the DD that "Mr Jones" did when he invested here years ago. A quick peek at the Preclinical graphs indicate that Kevetrin alone had a variable response to different tumor types and is not likely a one drug cure for all cancers. Talk about setting the bar too high. What he missed and what many BP's may be excited about is the ability of Kevetrin to increase the effectiveness of current chemotherapy drugs. I imagine that a lot of companies would be interested in something which can extend the income generated by their current drugs by extending the time to resistance.
" Big Pharma had plenty of time to check out the technology as Poly was dying. No interest. My concern now is the competition. In BOM, there is a Big Phama standard of care, and since the purchase, my count was at least 2 more well funded drugs have been approved, with another at the same stage as B."
Not sure how many times this needs to be stated, but I guess at least once more. At the time of the Polymedix asset purchase Antibiotics were not in vogue! Big Pharma was not interested because typical antibiotics are not a huge revenue generator and if a company has to spend the same amount of money developing a drug it would be better to develop a cancer drug with huge margins than spend the same amount to develop an antibiotic. The government has changed that environment by targeting Antibiotic development. (GAIN Act)
Not sure if he is referring to (Magic Mouthwashs) as (Big Pharma's) Standard of Care. I wasn't even aware that Big Pharma got to set the Standard of Care thought that was determined by the health care facilities. I believe Brilacidin is being compared to the current SOC which is Ice chips. Brilacidin showed a 90% reduction in the days with OM, what was the effectiveness of the drugs he referenced. How are those other drugs for medical device coating?
" I remember when I was doing my research about psoriasis 3 years ago, through as I recall some adjunct of the national P foundation, and I was stunned to see about 25 drugs in active development for the various kinds of psoriasis. It seemed like every billion dollar big pharma had a candidate, not wanting to miss out on that lucrative market. I am sure several have now been approved, and P still is sitting there. Bottom line for me is the competition is fearsome and well funded. "
Notice the word "CURED"
"By SAR, the lead candidate Prurisol is selected. Prurisol in human xenograft model. The top row animals show a clean coat with no evidence of psoriasis, essentially showing that Prurisol cured the psoriasis in the mice. The bottom row shows the untreated control animals. - See more at: http://cellceutix.com/prurisol/#sthash.ybeXKLlr.dpuf
"In laboratory studies, Prurisol was found to be effective against psoriasis in animal models, both in induced psoriasis as well as a xenograft model with human psoriatic tissue. As shown in the image, Prurisol removed virtually all signs of psoriasis with no reoccurrence of the lesions.
The trial is another milestone for Cellceutix and the culmination of years of work in its efforts to develop this drug for the chronic and often painful condition of plaque psoriasis. Despite advancements in therapeutics for treating this condition, there remains an area of great unmet medical need for an option to often-used biologics, which are known to have side effects and contraindications and eventually lose effectiveness to many patients. Prurisol is Cellceutix's efforts to provide a solution to this substantial market.
Read more: http://www.nasdaq.com/press-release/cellceuti...z3nHDZtQSD
